Navigation Links
Intellect Neurosciences, Inc. Receives Notice of Allowance and Completes Grant Requirements for Pivotal European Patent Related to Passive Immunization of Alzheimer's Disease
Date:4/10/2008

rest the progression of the disease. These symptomatic drugs are projected to generate approximately $4 billion in sales by 2008, indicating both the size of the market and the demand for effective treatment beyond symptomatic improvements.

About Intellect Neurosciences, Inc.

Intellect Neurosciences, Inc. is a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment and prevention of Alzheimer's disease and other disorders. The company has a broad proprietary immunotherapy platform for both passive and active immunization against Alzheimer's disease. Also, Intellect has recently completed Phase I clinical trials for OXIGON(TM), a unique antioxidant and anti-amyloid compound that has potential to treat Alzheimer's disease and other disorders. For additional information, please visit http://www.intellectns.com, or contact:

Elliot Maza, JD, CPA

President & Chief Financial Officer

Intellect Neurosciences, Inc.

7 West 18th Street, 9th Floor

New York, NY 10011, USA

Tel: 212-448-9300

Safe Harbor Statement Regarding Forward-Looking Statements

The statements in this release and oral statements made by representatives of Intellect relating to matters that are not historical facts (including without limitation those regarding future performance or financial results, the timing or potential outcomes of research collaborations or clinical trials, any market that might develop for any of Intellect's product candidates and the sufficiency of Intellect's cash and other capital resources) are forward- looking statements that involve risks and uncertainties, including, but not limited to, the likelihood that actual performance or results could materially differ, that future research will prove successful, the likelihood that any product in the research pipeline will receive regulatory approval
'/>"/>

SOURCE Intellect Neurosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
4. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
5. ActivBiotics Completes Sale of Fixed Assets; Expands Due Diligence Initiative for the Sale of Intellectual Property, Including Drug Product Candidates
6. Amarin Secures Global Intellectual Property Rights for Lipid Programs
7. ActivBiotics Intellectual Property Assets, Including Drug Product Candidates, Sold for $3.5 Million
8. Intradigm Licenses Key Next Generation RNA Interference (RNAi) Intellectual Property From University of Massachusetts Medical School
9. Dennis L. Smith Appointed Executive Chairman to Board of Directors of Solstice Neurosciences, Inc.
10. Dennis L. Smith Appointed President and Chief Executive Officer of Solstice Neurosciences, Inc.
11. Solstice Neurosciences, Inc. Issues Corporate Response to FDA Early Communication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 29, 2014  Sigma-Aldrich Corporation (NASDAQ: SIAL ... increased its investment in Green Chemistry and donated more ... last year, the Company announced Monday in its new ... the World? The report comes in ... being a responsible corporate citizen, including recognition for the ...
(Date:7/29/2014)... G-CON Manufacturing Inc., the standard in design and ... leadership appointment designed to drive the company’s ambitious growth ... Maik Jornitz, Chief Operating Officer of G-Con Manufacturing, has ... the pioneering company through its next phase of market ... and look forward to providing our next generation of ...
(Date:7/29/2014)... July 29, 2014 Dr. Jason Wendel – ... and named one of the Top 10 Plastic Surgeon Specialists ... skin care products. His complete line includes a Hydration Booster, ... give the face and skin a younger, more radiant appearance ... “Everyone’s skin is different, that is why at Dr. J. ...
(Date:7/28/2014)... A new method of building materials using light, developed ... day enable technologies that are often considered the realm ... devices. , Although cloaked starships won,t be a ... have developed for constructing materials with building blocks a ... to control the way that light flies through them, ...
Breaking Biology Technology:Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3G-CON Manufacturing, Inc. Announces Maik Jornitz as President 2Dr. J. J. Wendel Launches New Line of Skin Care Products 2Building 'invisible' materials with light 2
... The Netherlands, June 24 The U.S. Department,of Energy,s ... to enable the sale and delivery of an Avantium ... PNNL to,accelerate its catalyst research for infrastructure compatible biofuels ... by Battelle for the U.S. Department of Energy. The,Laboratory ...
... New Report Calls for a Broad Ethics of Emerging Technologies ... of synthetic biology will allow researchers to create biological parts ... to re-engineer existing organisms to perform novel and beneficial tasks. ... to addressing ethical and social issues is called for, especially ...
... WA, and VANCOUVER, June 24 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, ... the company has reached an agreement with the U.S. ... assessment process (SPA) on an amendment to the design ... lead product candidate targeting castrate resistant prostate cancer (CRPC). ...
Cached Biology Technology:Avantium to Deliver Flowrence System to Pacific Northwest National Laboratory (PNNL), USA 2Does Synthetic Biology Need Synthesized Ethics? 2Does Synthetic Biology Need Synthesized Ethics? 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 2OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 3OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 4OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer 5
(Date:7/29/2014)... researchers have developed an easier method to create ... work involved in diagnosing diseases. , DNA linked ... strong partnership that can be used in diagnostic ... which tag proteins with DNA can be ... and visualisation of biological material. The method also ...
(Date:7/29/2014)... There,s some good news for parents of preterm babies ... that by the time they become teenagers, the brains of ... born at term. , A study conducted by the University,s ... as the preterm child experiences no brain injury in early ... as good as their term-born peers. , However, the results ...
(Date:7/28/2014)... already approved by the U.S. Food and Drug Administration ... of certain bacterial pathogens inside human cells, including those ... The findings, published in mBio , the online ... a new way of identifying non-antibiotic drugs that could ... handful of drugs on the list inhibit the growth ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2
... predicted to occur under climate change scenarios has led many ... of wildfires. But a new study in the May issue ... changes in the types of plants growing in an area ... Philip Higuera of Montana State University and his colleagues ...
... Orleans, LA Sharell Bindom, a student in the ... will be awarded the Mead Johnson Research Award in ... the 2009 Experimental Biology Meeting April 18-22 in New ... is intended to recognize the graduate student, resident, or ...
... do all sorts of work, but a fundamental question has ... "There,s no little man sitting there, putting the protein ... biologist at the USC College of Letters, Arts and Sciences. ... tells them where to go in the cell." In ...
Cached Biology News:Plants could override climate change effects on wildfires 2Autopilot guides proteins in brain 2
... yolk protein Vtg in plasma from juvenile or ... for endocrine disrupting chemicals (EDCs) with estrogenic effects ... accepted screening test for the estrogenic effects of ... kit is a double-antibody immunometric (sandwich) EIA for ...
... acid synthetic peptide whose sequence corresponds to residues 115-133 of rat ... terminus): V115 - L - P - S - E ... V - P - N - E - V - L ... been added to facilitate conjugation and is not a part of ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
... Library Panels were designed for full-length gene ... PCRs to identify the desired cDNA clone. ... a 96-well "Master Plate," where each well ... identified the positive well(s) by gel electrophoresis ...
Biology Products: